WO2013138413A1 - Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts - Google Patents
Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts Download PDFInfo
- Publication number
- WO2013138413A1 WO2013138413A1 PCT/US2013/030688 US2013030688W WO2013138413A1 WO 2013138413 A1 WO2013138413 A1 WO 2013138413A1 US 2013030688 W US2013030688 W US 2013030688W WO 2013138413 A1 WO2013138413 A1 WO 2013138413A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- halogen
- amino
- 4alkyl
- heteroaryl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/0201—Oxygen-containing compounds
- B01J31/0204—Ethers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
- B01J31/0235—Nitrogen containing compounds
- B01J31/0239—Quaternary ammonium compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
- B01J31/0235—Nitrogen containing compounds
- B01J31/0244—Nitrogen containing compounds with nitrogen contained as ring member in aromatic compounds or moieties, e.g. pyridine
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
- B01J31/0271—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds also containing elements or functional groups covered by B01J31/0201 - B01J31/0231
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/0277—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides comprising ionic liquids, as components in catalyst systems or catalysts per se, the ionic liquid compounds being used in the molten state at the respective reaction temperature
- B01J31/0278—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides comprising ionic liquids, as components in catalyst systems or catalysts per se, the ionic liquid compounds being used in the molten state at the respective reaction temperature containing nitrogen as cationic centre
- B01J31/0285—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides comprising ionic liquids, as components in catalyst systems or catalysts per se, the ionic liquid compounds being used in the molten state at the respective reaction temperature containing nitrogen as cationic centre also containing elements or functional groups covered by B01J31/0201 - B01J31/0274
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/40—Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
- B01J2231/42—Catalytic cross-coupling, i.e. connection of previously not connected C-atoms or C- and X-atoms without rearrangement
- B01J2231/4205—C-C cross-coupling, e.g. metal catalyzed or Friedel-Crafts type
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/40—Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
- B01J2231/42—Catalytic cross-coupling, i.e. connection of previously not connected C-atoms or C- and X-atoms without rearrangement
- B01J2231/4205—C-C cross-coupling, e.g. metal catalyzed or Friedel-Crafts type
- B01J2231/4272—C-C cross-coupling, e.g. metal catalyzed or Friedel-Crafts type via enolates or aza-analogues, added as such or made in-situ, e.g. ArY + R2C=C(OM)Z -> ArR2C-C(O)Z, in which R is H or alkyl, M is Na, K or SiMe3, Y is the leaving group, Z is Ar or OR' and R' is alkyl
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/90—Catalytic systems characterized by the solvent or solvent system used
- B01J2531/98—Phase-transfer catalysis in a mixed solvent system containing at least 2 immiscible solvents or solvent phases
- B01J2531/985—Phase-transfer catalysis in a mixed solvent system containing at least 2 immiscible solvents or solvent phases in a water / organic solvent system
Definitions
- Cinchona alkaloid salts are known phase transfer catalysts useful in the asymmetric formation of carbon-carbon, carbon-heteroatom or carbon-halide bonds. See Takashi Ooi and Keiji Maruoka, Recent Advances in Asymmetric Phase-Transfer Catalysis, Angew. Chem. Int. Ed. 2007, 46, 4222-4266 ("Maruoka"). Maruoka reviews the various reactions in which phase-transfer catalysis is useful, including enantioselective alkylation, Michael addition, aldol and related reactions and Darzens reaction.
- the present invention is directed to novel bis-quarternary cinchona alkaloid salts and the use of bis-quarternary cinchona alkaloid salts in asymmetric phase transfer catalysis.
- the use of bis-quarternary cinchona alkaloid salts in asymmetric phase transfer catalysis surprisingly provides for a more active and efficient process as compared to mono-quarternary catalysts, providing high efficiency rates and asymmetric products in high enantiomeric excess.
- the invention is directed to novel bis-quarternary cinchona alkaloid salts and the use of bis-quarternary cinchona alkaloid salts in asymmetric phase transfer catalysis.
- the invention encompasses bis-quarternary cinchona alkaloid salts having the chemical structure of Formula I:
- R.1 is selected from ethyl and vinyl
- R2 is selected from hydrogen and methoxy
- R3 and R ⁇ are independently selected from the group consisting of Cj.galkyl, C2_6alkenyl, C2- galkynyl, C3_6cycloalkyl, aryl, heteroaryl, -Cj ⁇ alkyl-aryl and -Ci_4alkyl-heteroaryl, wherein C j.galkyl, C2-6alkenyl, C2-6alkynyl, C3.gcycloalkyl, aryl, heteroaryl and the aryl and heteroaryl portions of-Cj ⁇ alkyl-aryl and -Cj ⁇ alkyl-heteroaryl are optionally substituted with one to five substituents independently selected from R6,
- R 5 is selected from the group consisting of hydrogen, C(0)R, C(0)OR, CONRR', and Cj.galkyl
- R6 is selected from the group consisting of C i_4alkyl, Ci-4haloalkyl, aryl, Ci-4alkoxy, hydroxy, CN, C0 2 R, CONRR', SR, S0 2 R, SO3R, PR 2 , PO(OR) 2 , PO(OR) (NRR'), PO(NRR') 2 , P(OR) 2 , P(OR)(NRR*), P(NRR')2, SiRR'R", B(OR) 2 , C(0)R, NRR', NO2, and halogen,
- each R, R' and R" is independently selected from the group consisting of, H, Cj.galkyl, hydroxyl, C j.galkoxy, aryl, heteroaryl, -CH 2 -aryl, -CH 2 -heteroaryl, and
- each X and Y are independently anions selected from halide, OH, HSO4, SO4, BF4, SbF6, carboxylate, carbonate, hydrogencarbonate, NO3, sulfonate, hexafluorophosphate, phosphate, hydrogen phosphate and perchlorate,
- phase transfer catalysts for use as phase transfer catalysts in the stereoselective formation of a carbon-carbon, carbon- heteroatom or carbon-halide bond on a substrate in a biphasic medium comprising an aqueous phase and organic phase or a micelle medium.
- the cinchona alkaloid salts of Formula I encompass all stereoisomers, including cinchonine, cinchonidine, quinine, quinidine, dihydroquinidine, and dihydroquinine.
- the invention encompasses the bis-quarternary cinchona alkaloid salts of Formula I for use as phase transfer catalysts in one of the following asymmetric reactions: (1) alkylation with an electrophilic alkylating agent, (2) Michael addition with an electron deficient olefin, (3) aldol reaction with an aldehyde, (4) Mannich reaction with a a- imino ester, (5) Darzens reaction with an aldehyde, (6) Neber rearrangement of an oxime into an a-aminoketone, (7) epoxidation of an electron deficient olefin, (8) aziridination of an electron deficient olefin, (9) dihydroxylation of an electron deficient olefins, (10) fluorination of a carbonyl substrate, and (1 1) sulfenylation of a ⁇ -keto sulfoxide.
- the aforementioned reactions are well know in the art and described by Maruoka.
- Q forms a fused 5- or 6-membered aromatic carbocyclic or heterocyclic ring, each optionally substituted with 1 to 4 RC groups,
- each RA and each are independently hydrogen, halogen, hydroxy, amino or an organic substituent group, and one R ⁇ and one R ⁇ may be joined together to form a mono-, bi- or tricyclic carbocyclic or heterocyclic ring system, optionally substituted with 1 to 4 RC groups,
- RC is hydrogen, halogen, hydroxy, amino or an organic substituent group
- PG is a nitrogen protecting group
- W is a functional group that has leaving ability, in a water-immiscible organic phase in the presence of a bis-quarternary cinchona alkaloid salt and a base in an aqueous phase to form a biphasic medium comprising the aqueous phase and water-immiscible organic phase, wherein the bis-quarternary cinchona alkaloid salt has the chemical structure of Formula I:
- Rl is selected from ethyl and vinyl
- R2 is selected from hydrogen and methoxy
- R3 and R ⁇ are independently selected from the group consisting of Cj.galkyl, C2-6alkenyl, C2- 6alkynyl, C3_6cycloalkyl, aryl, heteroaryl, -Ci ⁇ alkyl-aryl and -Ci ⁇ alkyl-heteroaryl, wherein C j.galkyl, C2-6alkenyl, C2-6alkynyl, C3_6cycloalkyl, aryl, heteroaryl and the aryl and heteroaryl portions of-C i_4alkyl-aryl and -C j ⁇ alkyl-heteroaryl are optionally substituted with one to five substituents independently selected from R6,
- R 5 is selected from the group consisting of hydrogen, C(0)R, C(0)OR, CONRR', and C j.galkyl
- R.6 is selected from the group consisting of Ci-4alkyl, Ci-4haloalkyl, aryl, Cj-4alkoxy, hydroxy,
- each R, R' and R" is independently selected from the group consisting of, H, Cj ⁇ alkyl, hydroxy and Ci _4alkoxy, and
- each X and Y are independently anions selected from halide, OH, HSO4, SO4, BF4, SbFg, carboxylate, carbonate, hydrogencarbonate, NO3, sulfonate, hexafluorophosphate, phosphate, hydrogen phosphate and perchlorate,
- each R ⁇ and each R ⁇ are independently selected frorn the group consisting of:
- R ⁇ and R ⁇ together may complete a mono- or bicyclic carbocyclic or heterocyclic system of up to 10 ring atoms which optionally bears up to 3 substituents independently selected from halogen, OH, oxo, CN, CF 3 , R 8 , OR 7 , SR 8 , SO2R 8 , S0 2 N(R 7 )2,
- R 7 is H or Cj.galkyl which is optionally substituted with up to 3 halogen atoms or with OH, CN, CF3, Cj ⁇ alkoxy, amino, Cj ⁇ alkylamino or di(Ci_4alkyl)amino, or R 7 is phenyl, benzyl or 5- or 6-membered heteroaryl, any of which optionally bears up to 3 substituents independently selected from halogen, OH, CN, CF3, Cj ⁇ alkyl, Ci_4alkoxy, amino, C ⁇ .
- R 7 groups attached to the same nitrogen atom may complete a heterocycle of up to 6 ring atoms which optionally bears up to 3 substituents independently selected from halogen, OH, oxo, CN, CF3, C ⁇ alkyl, Cj ⁇ alkoxy, amino, C ⁇ alkylamino and di(Ci_
- R 8 is C j .galkyl which is optionally substituted with up to 3 halogen atoms or with OH, CN, CF3, Ci_4alkoxy, amino, Cj ⁇ alkylamino or di(Ci_4alkyl)amino, or R 8 is phenyl, benzyl or 5- or 6-membered heteroaryl, any of which optionally bears up to 3 substituents independently selected from halogen, OH, CN, CF3, C ⁇ _4alkyl, C 1 _4alkoxy, amino, C ⁇ .
- R 8 groups attached to the same nitrogen atom may complete a heterocycle of up to 6 ring atoms which optionally bears up to 3 substituents independently selected from halogen, OH, oxo, CN, CF3, Cj ⁇ alkyl, Cj ⁇ alkoxy, amino, Cj ⁇ alkylamino and di(Cj.
- R 7 is H or C ⁇ _6alkyl which is optionally substituted with Up to 3 halogen atoms or with OH, CN, CF3, Cj ⁇ alkoxy, amino, C malkylamino or di(Ci_4alkyl)amino, or R 7 is phenyl, benzyl or 5- or 6-membered heteroaryl, any of which optionally bears up to 3 substituents independently selected from halogen, OH, CN, CF3, C j _4alkyl, C j ⁇ alkoxy, amino, C ⁇ .
- R 7 groups attached to the same nitrogen atom may complete a heterocycle of up to 6 ring atoms which optionally bears up to 3 substituents independently selected from halogen, OH, oxo, CN, CF3, C ⁇ alkyl, Ci_4alkoxy, amino, Ci_4alkylamino and di(Cj_
- R 8 is Ci_6alkyl which is optionally substituted with up to 3 halogen atoms or with OH, CN, CF3, Cj_4alkoxy, amino, Cj ⁇ alkylamino or di(Ci_4alkyl)amino, or R 8 is phenyl, benzyl or 5- or 6-membered heteroaryl, any of which optionally bears up to 3 substituents independently selected from halogen, OH, CN, CF3, Cj ⁇ alkyl, C j ⁇ alkoxy, amino, C ⁇ .
- R 8 groups attached to the same nitrogen atom may complete a heterocycle of up to 6 ring atoms which optionally bears up to 3 substituents independently selected from halogen, OH, oxo, CN, CF3, C j ⁇ alkyl, Cj ⁇ alkoxy, amino, Cj ⁇ alkylamino and di(C i_
- the invention encompasses the aforementioned process wherein in Formula A PG is selected from the group consisting of: Cj.g alkyl, vinyl,
- the invention encompasses the aforementioned process wherein in Formula A W is selected from the group consisting of: halogen and sulfonate.
- the invention encompasses the aforementioned process wherein the water-immiscible organic phase is selected from the group consisting of benzene, toluene, xylenes, chlorobenzene, ethyl ether, isopropyl ether, tetrahydrofliran, 2-methyl tetrahydrofuran, dioxane, methyl tert-butyl ether, cyclopentyl methyl ether, isopropyl acetate, ethyl acetate, hexanes, heptanes, cyclohexane, dichloromethane and dichloroethane.
- the water-immiscible organic phase is selected from the group consisting of benzene, toluene, xylenes, chlorobenzene, ethyl ether, isopropyl ether, tetrahydrofliran, 2-methyl tetrahydrofuran, dioxan
- the inventidn encompasses the aforementioned process the base is selected from the group consisting of: sodium hydroxide, lithium hydroxide, potassium hydroxide, sodium carbonate, lithium carbonate, potassium carbonate, cesium hydroxide, cesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, lithium hydrogen carbonate, cesium hydrogen carbonate, lithium fluoride, sodium fluoride, potassium fluoride, cesium fluoride, lithium tert-butoxide, sodium tert-butoxide, potassium tert- butoxide, sodium phosphate, lithium phosphate and potassium phosphate.
- the invention encompasses the aforementioned process wherein the water-immiscible organic phase is toluene and the base is sodiurri hydroxide.
- the invention also encompasses the bis-quartefnary cinchona alkaloid salts of Formula I for use as a phase transfer catalyst in one of the following reactions:
- G is N or CH
- R.i, R.ii and R* u are independently H, halogen or an organic substituent group
- R iv is selected from -OR v ,SR vi and NR vii R viii , whereih R v and R vi are independently U or an organic substituent group, R vu and R vm are independently H or an organic substituent group or R vn and R vm may be joined together with the nitrogen to which they are attached to form a 5- or 6-membered heterocyclic ring, and when G is N, R" and R u ' may be joined together with the atoms to which they are attached to form a 5- or 6-membered mono- or 9- or 10-membered bi-cyclic ring containing one Or more heteroatoms in addition to the nitrogen, said ring optionally substituted with 1 to 5 substituents independently selected from: halogen, hydroxy, amino or an organic substituent group;
- n 0 or 1
- ring T is optional and forms a fused 5- or 6-membered aromatic carbocyclic or heterocyclic ring, each ring optionally substituted with hydrogen, halogen, hydroxy, amino or an organic substituent group and R* x is H or an organic substituent group,
- n is 0 or 1
- ring T is optional and forms a fused 5- or 6-membered aromatic carbocyclic or heterocyclic ring, each ring optionally substituted with hydrogen, halogen, hydroxy, amino or an organic substituent group and R x is selected from -OR x, ,SR xn and NR X1U R X1V , wherein R 1 and R x " are independently H or an organic substituent group and R x ' n and R x ' v are independently H or an organic substituent group or R xm and R X1V may be joined together with the nitrogen to which they are attached to form a 5- or 6-membered heterocyclic ring;
- each EWG is independently an electron withdrawing group; comprising reacting the substrate with electrophilic alkylating agent, an electron deficient olefin or an aldehyde in the presence of bis-quarternary cinchona alkaloid salt and a base in a biphasic medium comprising an aqueous phase and organic phase to form the carbon-carbon bond.
- the invention also encompasses bis-quarternary cinchona alkaloid salts having the chemical structure of Formula II:
- R1 is selected from ethyl and vinyl
- R2 is selected from hydrogen and methoxy
- Ar 1 is aryl or heteroaiyl, wherein said aryl and heteroaryl groups are optionally substituted with one to five substituents independently selected from R3,
- Ar 2 is aryl or heteroaryl, wherein said aryl and heteroaryl groups are optionally substituted with one to five substituents independently selected from R3,
- each X and Y are independently anions selected from halide, OH, HSO4, SO4, BF4, SbF , carboxylate, carbonate, hydrogencarbonate, NO3, sulfonate, hexafluorophosphate, phosphate, hydrogen phosphate and perchlorate.
- the cinchona alkaloid salts of Formula II encompass all stereoisomers, including cinchonine, cinchonidine, quinine, quinidine, dihydroquinidine, and dihydroquinine.
- An embodiment of the invention encompasses bis-quarternary cinchoria alkaloid salts of Formula II wherein Ar 1 is phenyl which is optionally substituted with one to five substituents independently selected from R3, and Ar 2 is phenyl which is optionally substituted with one to five substituents independently selected from R3.
- An embodiment of the invention encompasses bis-quarternary cinchona alkaloid salts of Formula Ha wherein R.1 is vinyl and R.2 is methoxy.
- Another embodiment of the invention encompasses bis-quarternary cinchona alkaloid salts of Formula Ila wherein R.3 is selected from halogen and methoxy.
- R is selected from the group consisting of vinyl and ethyl
- R is selected from the group consisting of vinyl and ethyl; R 3 is selected from the following groups:
- alkyl refers to a monovalent straight or branched chain, saturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range.
- Ci -6 alkyl (or “CJ-C6 alkyl”) refers to any of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and iso- propyl, ethyl and methyl.
- Ci -4 alkyl refers to n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl.
- Ci-3 alkyl refers to n-propyl, isopropyl, ethyl and methyl.
- haloalkyl means an alkyl radical as defined above, unless otherwise specified, that is substituted with one to five, preferably one tb three halogen. Representative examples include, but are not limited to trifluoromethyl, dichtoroethyl, and the like.
- acyl means -C(0)-alkyl where alkyl is as defined above.
- alkoxy means -O-alkyl whefe alkyl is as defined above.
- alkenyl refers to a monovalent straight or branched chain, saturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range and at least one carbon-carbon double bond, and otherwise carbon-cafbon single bonds.
- Alkenyl includes for example ethenyl, 1-methylethynyl, 2-propenenyl, 2-butenyl, 1,4-pentadienyl and the like.
- alkynyl refers to a monovalent straight or branched chain, saturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified rangei and at least one carbon-carbon triple bond, and otherwise carbon-carbon double or single bonds.
- Alkynyl includes for example 2-propynyl, 1 -butynyl, 3-hexen-5-ynyl and the like.
- cycloalkyl refers to any monocyclic ring of an alkane having a number of carbon atoms in the specified range.
- C3-6 cycloalkyl (or “C3-C6 cycloalkyl”) refers to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl
- C3-5 cycloalkyl refers to cyclopropyl, cyclobutyl, and cyclopentyl.
- halogen refers to fluorine, chlorine, bromine and iodine (alternatively referred to as fluoro, chloro, bromo, and iodo).
- aryl refers to phenyl, naphthyl, dnd anthranyl.
- heteroaryl refers to (i) a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, or (ii) is a heterobicyclic ring selected from quinolinyl, isoquinolinyl, and quinoxalinyl.
- Suitable 5- and 6- membered heteroaromatic rings include, for example, pyridyl (also referred to as pyridinyl), pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thienyl, furanyl, imidazolyl, pyrazolyl, triazolyl, oxazolyl, isooxazolyl, oxadiazolyl, oxatriazolyl, thiazolyl, isothiazolyl, and thiadiazolyl.
- Heteroaryls of particular interest are pyrrolyl, imidazolyl, pyridyl, pyrazinyl, quinolinyl (or quinolyl), isoquinolinyl (or isoquinolyl), and quinoxalinyl.
- Examples of 4- to 7-membered, saturated heterocyclic rings within the scope of this invention include, for example, azetidinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, pyrrolidinyl, imidazolidinyl, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrazolidinyl, hexahydropyrimidinyl, thiazinanyl, thiazepanyl, azepanyl, diazepanyl, tetrahydropyranyl, tetrahydrothiopyranyl, and dioxanyl.
- Examples of 4- to 7-membered, unsaturated heterocyclic rings within the scope of this invention include mono-unsaturated heterocyclic ritigs corresponding to the saturated heterocyclic rings listed in the preceding sentence in which a single bond is replaced with a double bond (e.g., a carbon-carbon single bond is replaced with a carbon-carbon double bond).
- any of the various cyclic rings and ring systems described herein may be attached to the rest of the compound at any ring atom (i.e., any carbon atom or any heteroatom) provided that a stable compound results.
- a heteroaromatic ring described as containing from “1 to 4 heteroatoms” means the ring can contain 1 , 2, 3 or 4 heteroatoms. It is also understood that any range cited herein includes within its scope all of the sub-ranges within that range. Thus, for example, a heterocyclic ring described as containing from “1 to 4 heteroatoms” is intended to include as aspects thereof, heterocyclic rings containing 2 to 4 heteroatoms, 3 or 4 heteroatoms, 1 to 3 heteroatoms, 2 or 3 heteroatoms, 1 or 2 heteroatoms, 1 heteroatom, 2 heteroatoms, 3 heteroatoms, and 4 heteroatoms.
- an aryl or heteroaryl described as optionally substituted with "from 1 to 4 substituents” is intended to include as aspects thereof, an aryl or heteroaryl substituted with 1 to 4 substituents, 2 to 4 substituents, 3 to 4 substituents, 4 substituents, 1 to 3 substituents, 2 to 3 substituents, 3 substituents, 1 to 2 substituents, 2 substituents, and 1 substituent.
- any variable occurs more than one time in any constituent or in Formula I, II, Ila, A, B or C, or in any other formula depicting and describing compounds of the present invention
- its definition on each occurrence is independent of its definition at every other occurrence.
- combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
- substitution by a named substituent is permitted on any atom in a ring (e.g., cycloalkyl, aryl, or heteroaryl) provided such ring substitution is chemically allowed and results in a stable compound.
- the compounds of the invention contain chiral centers and, as a result of the selection of substituents and substituent patterns, can contain additional chiral centers, and thus can occur as mixtures of stereoisomers, or as individual diastereomers, or enantioniers. All isomeric forms of these compounds, whether individually or in mixtures, are within the scope of the present invention. Unless depicted or specified otherwise* the cinchona alkaloid salts of the invention encompass all stereoisomers, including cinchonine, ciiichonidine, quinine, quinidine, dihydroquinidine, and dihydroquinine.
- organic substituent group means any substituent group containing a carbon atom, which may be optionally substituted.
- Organic substituent groups include, but are not limited to, C i . i oalkyl, C2- 1 oalkenyl, C2- 1 oalkynyl, aryl, heteroaryl, non- or partially aromatic heterocycles, C3.i Qcycloalkyl, C j.i oalkoxy, Ci ⁇ Qalkylthio, and C j.i oacyl, each optionally substituted with, for example, one or more of the following: halide, hydroxy, nitrogen containing substituents such as amino, sulfur containing substituent such as sulfates, C j ⁇ alkoxy and Ci _4alkylthio.
- nitrogen protecting group means a substituent that protects a nitrogen atom in a reaction from a reagent or chemical environment.
- Nitrogen protecting groups are well known in the art and include for example, /-butyl, vinyl, phenyl, benzyl, -methoxybenzyl, 3,4- dimethoxy benzyl, /?-nitrobenzyl, benzhydryl, trityl, trialkylsilyl, methoxymethyl ether, (2,2,2- trichloroethoxy)methyl and 2-(trimethylsilyl)ethoxy)methyl, Boc, Cbz.
- the term "functional group that has leaving ability” means an atom or atom group that leaves from a substrate in a substitution or elimination reaction, that is a leaving group, and includes for example halogen and sulfonate.
- electrophilic alkylating agent means an agent that delivers the equivalent of an alkyl cation, such as for example an alkyl halide.
- sulfonate means an anion or leaving group having the formula R#.
- R which is the conjugate base of sulfonic acid.
- R includes for example C j ⁇ alkyl optionally substituted with 1 to 3 halogen, and aryl optionally substituted with 1 to 3 halogen or methyl or nitro. Examples include mesylate, triflate, tosylate and besylate.
- electron withdrawing group is well known in the art are includes for example, cyano, nitro, -C(0)OR xvii ,-C(0)SR x viii and -C(0)NR xvix R xx , wherein R x ii and Rxviii are independently H or an organic substituent group and R Xv,x and R xx are independently H or an organic substituent group or R v i x and R xx may be joined together with the nitrogen to which they are attached to form a 5- or 6-membered heterocyclic ring;
- DCPP l,3-bis(dicyclohexylphosphino)propane
- NMP N-methyl-2-pyrrolidone
- the resulting slurry was aged at 22 °C for 1 to 2 h, filtered, rinsed with AcOEt (2 x 24 ml), then hexane (2 x 24 ml). The solid was dried under vacuum to give powder as a mixture of bis-salts (bis-quinidine salt 10 and bis-dihydroquinidine salt). (Total 19.7 g, 94% yield).
- the authentic sample of 10 was purified by SFC (IC column, 20 x 250 mm, 60% MeOH/C02, 50 mL/min, 100 bar, 35°C, 220 nm, sample concentration: 133 mg/mL in MeOH; desired peak: 3 to 4.5 min).
- a slurry cinchonidine (5.0 g, 16.98 mmol) and 2-cyano-benzyl bromide (4.0 g, 20.38 mmol) in 50 ml of IPA was degassed by vacuum and flushed with N 2 , then it was heated to 67 °C until completely conversion (4 to 5 h). It was cooled down and ⁇ 40 mL of solvent was removed by reducing pressure. This concentrated solution was added into AcOEt (160 ml) over 5 to 10 min while stirring.
- the resulting slurry was aged for 1 to 2 h at 22 °C, filtered, rinsed with IPA/hexane (1 : 1 ; 50 ml) and dried under vacuum to give 19 as a solid (7.43 g, 89% ⁇ ).
- the bis-quaternary catalyst is much more active and efficient as compared to the mono-quaternary catalyst for the spirocyclization reaction shown.
- the bis-catalysts contained -12 to 15% of the double saturated compounds hydroquinidine or hydrocinchonine.
- Tables 2 and 3 show a SAR study of bis-quaternary PTC catalysts for spirocyclization. Both bis-quaternary quinidine and cinchonine catalysts are very efficient (Entries 2 to 5). The Bis-Quinidine catalyst is relatively better than bis-cinchonine catalyst (Entry 2 and 3). 2-Bromo-5-Methoxy-benzyl group is the optimized group for this reaction.
- Table 4 shows a study of different functional groups.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (20)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013232191A AU2013232191B2 (en) | 2012-03-14 | 2013-03-13 | Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts |
| US14/384,355 US9376431B2 (en) | 2012-03-14 | 2013-03-13 | Bis-quaternary cinchona alkaloid salts as asymmetric phase transfer catalysts |
| ES13761100T ES2806150T3 (es) | 2012-03-14 | 2013-03-13 | Sales alcaloides de cincona bis-cuaternaria como catalizadores de transferencia de fases asimétricos |
| KR1020197038179A KR102153850B1 (ko) | 2012-03-14 | 2013-03-13 | 비대칭 상 이동 촉매로서의 비스-4급 신코나 알칼로이드 염 |
| EP23217661.0A EP4357020A3 (en) | 2012-03-14 | 2013-03-13 | Asymmetric phase transfer catalysis |
| CA2865941A CA2865941A1 (en) | 2012-03-14 | 2013-03-13 | Bis-quaternary cinchona alkaloid salts as asymmetric phase transfer catalysts |
| EP13761100.0A EP2825536B1 (en) | 2012-03-14 | 2013-03-13 | Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts |
| KR1020147025142A KR102061180B1 (ko) | 2012-03-14 | 2013-03-13 | 비대칭 상 이동 촉매로서의 비스-4급 신코나 알칼로이드 염 |
| MX2014010999A MX351657B (es) | 2012-03-14 | 2013-03-13 | Sales de alcaloide de cinchona bis-cuaternarias como catalizadores de transferencia de fase asimétrica. |
| CN201380013400.XA CN104144929B (zh) | 2012-03-14 | 2013-03-13 | 作为不对称相转移催化剂的金鸡纳生物碱双季盐 |
| RU2014141166A RU2667909C2 (ru) | 2012-03-14 | 2013-03-13 | Бисчетвертичные соли алкалоида хинного дерева в качестве асимметрических межфазных катализаторов |
| JP2015500539A JP6140266B2 (ja) | 2012-03-14 | 2013-03-13 | 不斉相間移動触媒としてのビス四級シンコナアルカロイド塩 |
| EP21202495.4A EP4019516A1 (en) | 2012-03-14 | 2013-03-13 | Asymmetric phase transfer catalysis |
| BR112014021828A BR112014021828B8 (pt) | 2012-03-14 | 2013-03-13 | Sal de alcaloide bisquaternário |
| EP20154142.2A EP3680240A1 (en) | 2012-03-14 | 2013-03-13 | Asymmetric phase transfer catalysis |
| AU2017204464A AU2017204464B2 (en) | 2012-03-14 | 2017-06-29 | Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts |
| AU2019206049A AU2019206049B2 (en) | 2012-03-14 | 2019-07-17 | Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts |
| AU2021204629A AU2021204629A1 (en) | 2012-03-14 | 2021-07-01 | Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts |
| AU2023254886A AU2023254886A1 (en) | 2012-03-14 | 2023-10-24 | Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts |
| AU2025220879A AU2025220879A1 (en) | 2012-03-14 | 2025-08-25 | Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261610746P | 2012-03-14 | 2012-03-14 | |
| US61/610,746 | 2012-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2013138413A1 true WO2013138413A1 (en) | 2013-09-19 |
Family
ID=49161748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2013/030688 Ceased WO2013138413A1 (en) | 2012-03-14 | 2013-03-13 | Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9376431B2 (https=) |
| EP (4) | EP2825536B1 (https=) |
| JP (1) | JP6140266B2 (https=) |
| KR (2) | KR102061180B1 (https=) |
| CN (1) | CN104144929B (https=) |
| AU (6) | AU2013232191B2 (https=) |
| BR (1) | BR112014021828B8 (https=) |
| CA (1) | CA2865941A1 (https=) |
| ES (1) | ES2806150T3 (https=) |
| MX (1) | MX351657B (https=) |
| RU (1) | RU2667909C2 (https=) |
| WO (1) | WO2013138413A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013169348A1 (en) | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Process for making cgrp receptor antagonists |
| WO2021225835A1 (en) * | 2020-05-06 | 2021-11-11 | Amgen Inc. | Synthesis of vinylic alcohol intermediates |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI487706B (zh) * | 2010-11-12 | 2015-06-11 | Merck Sharp & Dohme | 六氫吡啶酮甲醯胺氮雜茚滿cgrp受體拮抗劑 |
| US9487523B2 (en) | 2012-03-14 | 2016-11-08 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| JP6491669B2 (ja) | 2014-02-05 | 2019-03-27 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Cgrp活性化合物の錠剤製剤 |
| EP3463929B1 (en) * | 2016-06-07 | 2020-05-13 | Pirelli Tyre S.p.A. | Tire for vehicle wheels |
| MX391164B (es) * | 2017-05-30 | 2025-03-21 | Dot Therapeutics 1 Inc | Metodo para producir compuesto opticamente activo |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| CN109180606B (zh) * | 2018-09-30 | 2021-04-06 | 浙江工业大学 | 一类具有光学活性的β-氨基酮的合成方法 |
| CN116390712A (zh) | 2020-07-29 | 2023-07-04 | 阿勒根制药国际有限公司 | 治疗偏头痛 |
| CA3206184A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| WO2023049920A1 (en) | 2021-09-27 | 2023-03-30 | Allergan Pharmaceuticals International Limited | Combination comprising atogepant for treating migraine |
| CN115974867B (zh) * | 2023-01-31 | 2025-11-28 | 成都大学 | 一种手性相转移催化剂及其制备方法和应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0438796A2 (en) * | 1990-01-22 | 1991-07-31 | Hoechst-Roussel Pharmaceuticals Incorporated | Process for the enantioselection synthesis of alkylated oxindoles used as intermediates in the preparation of physostigmine |
| US6313247B1 (en) * | 1996-06-05 | 2001-11-06 | Wolfgang Lindner | Cinchonan based chiral selectors for separation of stereoisomers |
| US20020115896A1 (en) * | 2000-07-13 | 2002-08-22 | Pochapsky Thomas C. | Asymmetric synthetic methods based on phase transfer catalysis |
| US20070020182A1 (en) * | 2003-06-27 | 2007-01-25 | Geddes Chris D | Quaternary nitrogen heterocyclic compounds for detecting aqueous monosaccharides in physiological fluids |
| WO2011005731A2 (en) * | 2009-07-08 | 2011-01-13 | Merck Sharp & Dohme Corp. | Process for making cgrp receptor antagonist |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0601286D0 (en) * | 2006-01-23 | 2006-03-01 | Sandoz Ag | Asymmetric synthesis |
| PL213306B1 (pl) * | 2008-02-04 | 2013-02-28 | Politechnika Lodzka | Sposób otrzymywania wzbogaconych enancjomerycznie produktów kondensacji z kwasów racemicznych lub kwasów o niskiej czystosci enancjomerycznej |
| US9487523B2 (en) | 2012-03-14 | 2016-11-08 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
| US9174989B2 (en) | 2012-05-09 | 2015-11-03 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
-
2013
- 2013-03-13 MX MX2014010999A patent/MX351657B/es active IP Right Grant
- 2013-03-13 ES ES13761100T patent/ES2806150T3/es active Active
- 2013-03-13 EP EP13761100.0A patent/EP2825536B1/en active Active
- 2013-03-13 WO PCT/US2013/030688 patent/WO2013138413A1/en not_active Ceased
- 2013-03-13 KR KR1020147025142A patent/KR102061180B1/ko active Active
- 2013-03-13 CN CN201380013400.XA patent/CN104144929B/zh active Active
- 2013-03-13 AU AU2013232191A patent/AU2013232191B2/en active Active
- 2013-03-13 US US14/384,355 patent/US9376431B2/en active Active
- 2013-03-13 RU RU2014141166A patent/RU2667909C2/ru active
- 2013-03-13 CA CA2865941A patent/CA2865941A1/en active Pending
- 2013-03-13 KR KR1020197038179A patent/KR102153850B1/ko active Active
- 2013-03-13 EP EP21202495.4A patent/EP4019516A1/en not_active Withdrawn
- 2013-03-13 JP JP2015500539A patent/JP6140266B2/ja active Active
- 2013-03-13 BR BR112014021828A patent/BR112014021828B8/pt active IP Right Grant
- 2013-03-13 EP EP20154142.2A patent/EP3680240A1/en not_active Withdrawn
- 2013-03-13 EP EP23217661.0A patent/EP4357020A3/en active Pending
-
2017
- 2017-06-29 AU AU2017204464A patent/AU2017204464B2/en active Active
-
2019
- 2019-07-17 AU AU2019206049A patent/AU2019206049B2/en active Active
-
2021
- 2021-07-01 AU AU2021204629A patent/AU2021204629A1/en not_active Abandoned
-
2023
- 2023-10-24 AU AU2023254886A patent/AU2023254886A1/en not_active Abandoned
-
2025
- 2025-08-25 AU AU2025220879A patent/AU2025220879A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0438796A2 (en) * | 1990-01-22 | 1991-07-31 | Hoechst-Roussel Pharmaceuticals Incorporated | Process for the enantioselection synthesis of alkylated oxindoles used as intermediates in the preparation of physostigmine |
| US6313247B1 (en) * | 1996-06-05 | 2001-11-06 | Wolfgang Lindner | Cinchonan based chiral selectors for separation of stereoisomers |
| US20020115896A1 (en) * | 2000-07-13 | 2002-08-22 | Pochapsky Thomas C. | Asymmetric synthetic methods based on phase transfer catalysis |
| US20070020182A1 (en) * | 2003-06-27 | 2007-01-25 | Geddes Chris D | Quaternary nitrogen heterocyclic compounds for detecting aqueous monosaccharides in physiological fluids |
| WO2011005731A2 (en) * | 2009-07-08 | 2011-01-13 | Merck Sharp & Dohme Corp. | Process for making cgrp receptor antagonist |
Non-Patent Citations (3)
| Title |
|---|
| BABIN ET AL.: "Halogen derivatives of quinoliniums and isoquinoliniums", BULLETIN DE LA SOCIETE DE PHARMACEI DE BORDEAUX, vol. 113, no. 3, 1974, pages 101 - 106, XP008174565 * |
| SU ET AL.: "Theoretical investigation on mechanism of asymmetric Michael addition of malononitrile to chalcones catalyzed by Cinchona alkaloid aluminium(III) complex", ORG. BIOMOL. CHEM., vol. 9, 2011, pages 6402, XP055165213 * |
| TAKASHI OOI; KEIJI MARUOKA: "Recent Advances in Asymmetric Phase-Transfer Catalysis", ANGEW. CHEM. INT. ED., vol. 46, 2007, pages 4222 - 4266 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013169348A1 (en) | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Process for making cgrp receptor antagonists |
| WO2021225835A1 (en) * | 2020-05-06 | 2021-11-11 | Amgen Inc. | Synthesis of vinylic alcohol intermediates |
| AU2021268573B2 (en) * | 2020-05-06 | 2024-06-06 | Amgen Inc. | Synthesis of vinylic alcohol intermediates |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017204464B2 (en) | Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts | |
| IL145150A (en) | Derivatives of xahydro-8, a10 -methanopyrido [6,5: 3 ', 2' pirano [[d – 3,2 azapine, and pharmaceutical preparations containing them | |
| AU2022215237B2 (en) | Methods of preparing indolinobenzodiazepine derivatives | |
| JP2025530222A (ja) | 2-置換ピペリジン誘導体、その製造方法及び医薬的用途 | |
| WO2017181012A1 (en) | Cinchonium betaine catalysts and methods of using same | |
| CA3216995A1 (en) | Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline-1,3-dione | |
| JP2012521993A (ja) | 縮合三環式スルホンアミドの製造プロセス | |
| Chen | Organometallic Enantiomeric Scaffolds in the Synthesis of Alkaloids: I. Homo-SN2'-like Reaction/Annulative Demetallation and the Application in the Synthesis of (+)-Isofebrifugine II. Uncatalyzed Electrophilic Carbon-Carbon Bond Forming Reactions of Pyranyl and Pyridinyl Molybdenum Complexes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13761100 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2013232191 Country of ref document: AU Date of ref document: 20130313 Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 2865941 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref document number: 20147025142 Country of ref document: KR Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 14384355 Country of ref document: US |
|
| ENP | Entry into the national phase |
Ref document number: 2015500539 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/010999 Country of ref document: MX |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2013761100 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2014141166 Country of ref document: RU Kind code of ref document: A |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014021828 Country of ref document: BR |
|
| ENP | Entry into the national phase |
Ref document number: 112014021828 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140903 |